Safety of Cat-PAD in Cat Allergic Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will investigate the safety of Cat-PAD administered as increasing single doses.
Epistemonikos ID: bbd9e442b3e32351b2addc493470894870079730
First added on: May 05, 2024